• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Financial Services

Don't Overreact to Dimon's Health Scare

Before you join in the JPMorgan selloff, keep a few things in mind.
By JIM CRAMER Jul 02, 2014 | 11:24 AM EDT
Stocks quotes in this article: JPM, AIG, INTC, BRK.B

Jamie Dimon is a revered banker, mostly because JPMorgan Chase (JPM) made a lot of right moves in the last few years, chiefly building up a fortress balance sheet that shielded the company from the big losses that so many other banks have taken. That's why the sad news that he has throat cancer is causing the stock of this Action Alerts PLUS name to get hit today.

Should the stock be bought into the weakness?

First, you have to understand that when a company issues a release saying a CEO has cancer but it is curable cancer, and curable in a relatively short period, as is the case here, it is not a reason for selling.

That's because no executive wants to make a positive prognosis about such a horrible disease unless the doctors have given a huge amount of assurance that things will turn out well in the end. The stakes are too high, even for banks, which have a very tarnished reputation when it comes to veracity.

Second, and more important for stock-pickers, there have been three times that stand out when a noteworthy CEO has had to be treated for curable forms of cancer: the 1995 admission from Intel's (INTC) then-CEO, Andy Grove, the 2010 statement from Bob Benmosche, CEO of American International Group (AIG) and the 2012 announcement from Warren Buffett at Berkshire Hathaway (BRK.B).

All three situations proved to be buying opportunities. Intel, which was admittedly in the midst of one of the great '86 microprocessing cycles, doubled in the year after Grove got sick and then returned. Within a month, AIG and Berkshire Hathaway were both higher after the tough news each company released. The companies were true to their word, and all three came back in short order to lead their companies to further success.

Now not to be too grisly, but just playing it ultra-safe, JPMorgan does have a strong bench of executives underneath Dimon, including Gordon Smith, the excellent head of the highly successful consumer bank, and, perhaps, ultimately, Matt Zames, the 43-year-old chief operating officer, although he's a little young to be thought of in in the successor role right now.

No bank runs itself. JPMorgan has had a fairly sterling reputation among banks, but it hasn't all been roses under Dimon, including the "London whale" incident that led to a multi-billion charge and the gigantic $13 billion hit to earnings that Dimon agreed to pay the government for past transgressions. The last quarter itself was nothing to write home about either -- it was one of the weaker in the group.

All that said, this is a quality franchise with a stock that has gotten very cheap compared with the overall market. I think it is, in the end, a proxy, not so much for Dimon's management but for the U.S. and world economy, which I think is improving. That means, to me, that it is a buy on any material weakness on this difficult news.

Tough to say "buying opportunity on curable cancer," but if history be the judge, it should be. 

Would you like to test drive all of TheStreet's premium products for free? Sign up for our all-access pass for July at absolutely no cost to you and read Action Alerts PLUS picks from me and Stephanie Link, Doug Kass' Daily Diary on Real Money Pro, Stocks Under $10 picks from David Peltier and much more. Learn more here. 

https://secure2.thestreet.com/cap/prm.do?OID=026557

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Action Alerts PLUS, which Cramer co-manages as a charitable trust, is long JPM.

TAGS: Investing | U.S. Equity | Financial Services | Technology | Stocks

More from Financial Services

Rocket Cos Won't Be Blasting Off From Here

Bruce Kamich
Jul 6, 2022 12:00 PM EDT

Let's check out the charts and indicators.

Progressive's Commercials Are Well Known, But What About Its Charts?

Bruce Kamich
Jul 5, 2022 11:54 AM EDT

Traders could probe the long side of PGR.

The Best House in This Neighborhood Is on Sale

Brad Ginesin
Jun 24, 2022 12:15 PM EDT

The buying opportunity here below book value is compelling.

Affirm: Will Investors Buying Now, Pay for It Later?

Bruce Kamich
Jun 22, 2022 3:12 PM EDT

Let's see what the charts and indicators suggest.

American International Is Breaking a Longer-Term Uptrend Line

Bruce Kamich
Jun 13, 2022 1:51 PM EDT

Is there more risk than reward?

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 09:41 AM EDT STEPHEN GUILFOYLE

    Reweighting Portfolio Positions Through 5 Trades

    Check out what we're doing in the TheStreet's Stoc...
  • 12:01 PM EDT PAUL PRICE

    A Recent Director Buy in Children's Place (PLCE)

    Four of the most recent insider trades in Children...
  • 07:34 AM EDT PAUL PRICE

    A $525,000 Vote of Confidence on Macerich (MAC)

  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login